Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It has maintained a robust intrinsic entertainment value. The investment value not so much.
Good press?
A uninterruptible backup power supply would be critical too.
dmb, manufacturing??? Memphis physical expansion was announced June 2015 just before screening halt became public knowledge. And Kings was announced in October 2015. A couple of good posts from Doc and Flipper discussing possibilities in 116820 and 116821. Let me add another possibility here. If a closed system or semi-closed system has been developed for L production could class 100 cleanrooms be implemented in conjunction with the closed or semi-closed systems? From what we know the sq footage of the up to 16 clean rooms going into the Memphis expansion appears to be a very tight.
They've got one shot (no pun intended) at making the vaccine implementing process automation in a closed or semi-closed system in a cleanroom environment would mitigate risk.
No, per DoGood's link its EGF. Another protein based growth factor easier and cheaper to produce. They're getting efficacy (long tail survival) in about 20% of lung cancer patients. Another "incremental" innovation. The next indication they intend to try is prostate. They mention other cancer vaccines including brain available in Cuba, but no specifics. As Doc points out some of these incremental innovations might have potential in combo trials .....especially if CI's combos end up not being the panacea many are hoping for.
Agree. Diet, exercise, smoking are big longevity factors and Cubans are on par with U.S. bad habits albeit they do smoke more Cuban cigars.
Couple of tidbits from last Friday's Vice episode.
Cuba spends less than a tenth per capita on healthcare compared to U.S. and is on par (longevity) or better (infant mortality) on many metics. They have similar rates of diabetes and have a drug/medication that eliminates up to 80% of diabetes related amputations. The drug/medication is available in every country worldwide except U.S.
I've stated the upcoming combo trial with BMY (BMS) has a lot to do with safety. As a BMY (BMS) shareholder I'd expect someone at a high pay grade had to approve as fingers would point to BMY if there is an AE/SAE.
A very fine and well respected institution of higher learning......
IU (or a IU hospital) is one of the DCvax-L trial locations.
You'll need subscription access.
http://www.hbo.com/vice/about/index.html
Interesting segment on Cuban cancer vaccine(s) on episode of the HBO series Vice last night. Worth a watch if you have access.
I trust the other BOD members will inform Cofer of the two drink minimum.
Welcome to the party Cofer.
Brings a new connotation to "no harm no foul".
Memphis expansion at Cognate came to light in June 2015. Kings was announced in October 2015. I perceived Kings to be a stopgap or contingency until Sawston would come online.
Would really be interesting if Carnell wanted LP on the board.
Protein based CI's are the smart initial play for BP's. CI's are not individualized (autologous) so are easier to manufacture (batch). As I've posted before one of my holdings BMY (BMS) is spending nearly $2bil to establish their biologic production on two continents. An autologous therapy will need to be proven before BP will jump onboard.
Should add TC out of penalty box date to calendar?
Thanks for posting updates on the jobs listings. Seems to make sense other positions would be filled after Head of Commerical Manufacting was filled as they assemble their team. And now adding IT support of the operation.
NBS had some play on this board around two years ago.
Status update on international filing, may simply be elapsed time generated, they filed in 117 countries. I'll talk to our IP counsel if there is more to it I'll post an update.
I know, however I didn't know if I should laugh or cry and I chose the former. We do have a litigiousness society. Case in point, when I lived in Seattle there were more lawyers in the Columbia Center (tallest building in Seattle) than all of Japan.
Good one (needle one too) and I like curry as a entrée.
Process automation could have a role in making the DCVac vaccine more efficacious too.
If Optune gains traction any bets on it also increasing claims that cell phones cause tumors? (RF radiation from cell phone is not same as what the Optune cap emits. Won't stop some from making connection-no pun intended)
Nice to see you drop in and partake in some of the banter.
Agreed, His shtick and well documeted lack of objectivity is more than questionable. The shtick is what drives the views at the street and on Twitter and gets devotees following and emulating.......sad
No. The lack of courtesy or moreover objectivity is well documented.
Adam has refuted the Enron claim more than once on this board. I would give him the benefit of the doubt, not that he gives LP same courtesy. Enron was a "boys club".
Part of the art of patent submission is to make the claims as broad as possible attempting to cover all the potential bases.
Superman had his phone booth.
I'm a BMY (BMS) shareholder. One would think a combo with something to help target the immune response holds promise in the I/O arena.
And Twitter makes it entertaining, (140 character limit is genius as it doesn't test the attention span of poster or viewer/reader in kind)
One of several anomalies today. What are the odds?
You are decidedly long tail Falconx.
Technically yes in regards to combo treatment. But I think another plausible way to look at this is Revimmune has IP (intellectual property or patents) on something Cognate intends to commercialize (they're not infringing or moreover there are no damages worth going to court for until commercialization). I suspect Cognate is simply clearing their path.
When I get some time I intend to look into this further.
Fair summation.
Have not had time to research this, but I'd suspect Revimmune would have some intellectual property (patent or patents) attractive to Cognate. And this assignment is part of cross license agreement.
Good thing they went light and slow on the manufacturing side of business. Even so under their current circumstances it's now a burden being addressed.